Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Health Care · CIK 0002062583
$18.29
+2.75% · delayed ~15 min
Last price from Oct 22, 2026
$5.14B market value
From MiniMed Group, Inc.'s FY2026 10-K, filed Jun 29, 2026 · read the filing
MiniMed makes medical devices and equipment. It took in $3.10B last year, which makes it a mid-sized company. It spends more than it earns — losing about 11 cents on every dollar of sales.
The financial picture is led by debt, with growth worth watching, while profitability remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From MiniMed Group, Inc.'s FY2026 annual filing · share price scored separately
Largest year-over-year changes in FY2026
Profit
-$213.0M → -$333.0M
Free cash flow
-$53.0M → -$420.0M
Earnings per share
-$0.84 → -$1.19
Cash
$11.0M → $298.0M
Measured against FY2025, from the 10-K filed Jun 29, 2026
Deteriorated: $120.0M wider
-$213.0M to -$333.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
MMED rose 2.75% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 1.1 points above its sector and 3.8 points above the market.
No filing from MMED and no news item about it appeared in the last 3 days.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 18 analysts covering this company, as of . Their views, not this site's.
Of 18 analysts publishing on this company, 5 say strong buy, 11 say buy and 2 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $333.0M last year, losing about 11 cents on every dollar of sales.
Slowly. Sales grew 14.3% last year.
It does not appear so. For every $1 it owes, it owns $4.54 in assets.
Core operating and valuation reference metrics
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2026 annual filing
Last year it lost $333.0M and generated -$197.0M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202610-K · Jun 29, 2026Filing for FY2026 | FY202510-K · Jun 29, 2026Filing for FY2025 | FY202410-K · Jun 29, 2026Filing for FY2024 | ChangeFY2026 vs FY2025 |
|---|---|---|---|---|
| RevenueWhat is this? | $3.10B | $2.71B | $2.47B | +14.3% |
| Cost of revenue | $1.42B | $1.19B | $1.03B | +19.8% |
| Gross profit | $1.68B | $1.53B | $1.44B | +9.9% |
| Gross marginGross profit ÷ revenueWhat is this? | 54.2% | 56.3% | 58.2% | −2.1 pts |
| Selling, general and administrative | $1.18B | $1.08B | $1.06B | +9.5% |
| Operating income | -$190.0M | -$146.0M | -$69.0M | −30.1% |
| Operating marginOperating income ÷ revenueWhat is this? | -6.1% | -5.4% | -2.8% | −0.7 pts |
| Income before tax | -$189.0M | -$147.0M | -$70.0M | −28.6% |
| Net income | -$333.0M | -$213.0M | -$112.0M | −56.3% |
| Net marginNet income ÷ revenueWhat is this? | -10.7% | -7.8% | -4.5% | −2.9 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-1.19 | $-0.8426 | $-0.443 | −40.7% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| MMEDMiniMed Group, Inc. · this page | 6.0/10 | 3/8 | 14.3% | -10.7% | — |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Was granted or awarded shares — 1,800 shares
Holds 174,545 shares after this filing.
Was granted or awarded shares — 11,108 shares
Holds 326,266 shares after this filing.
19 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Changed control of the company · Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingHeld a shareholder vote
Read the filingWrite down why you are following MiniMed Group, Inc., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 34 subsidiaries named in its 10-K, incorporated across 26 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from MMED's 10-K for fiscal year 2026 (period ending 2026-04-24, filed Jun 29, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2026 | 6.0 | 3/8 | 10-K, filed Jun 29, 2026 |
| FY2025 | 6.0 | 3/5 | 10-K, filed Jun 29, 2026 |
| FY2024 | 2.0 | 2/2 | 10-K, filed Jun 29, 2026 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
3 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
3.69
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2026 filing as filed with the SEC.
Deteriorated: $367.0M wider
-$53.0M to -$420.0MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: $0.34 wider
-$0.84 to -$1.19Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +2609.1%
$11.0M to $298.0MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +11.1%
252.8M to 280.8MCritical
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Deteriorated: $44.0M wider
-$146.0M to -$190.0MSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Changed: +15.5%
$193.0M to $223.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +14.3%
$2.71B to $3.10BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +9.9%
$1.53B to $1.68BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: −2.1 pts
56.3% to 54.2%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Deteriorated: −2.9 pts
-7.8% to -10.7%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Q1 FY2027 against Q1 FY2027, from the 10-Q filed Sep 8, 2026 — read it.
Improved: turned positive
-$13.0M to $5.0MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: $19.0M narrower
-$19.0M to $0.00Critical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: $104.0M narrower
-$194.0M to -$90.0MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: $0.08 narrower
-$0.08 to $0.00Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +2200.0%
$9.0M to $207.0MCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: +11.2%
252.8M to 281.2MCritical
Why it matters: New shares divide the same company into more pieces, so each existing holding owns slightly less of it. Often pay for staff or an acquisition rather than anything wrong.
Improved: +16.6%
$723.0M to $843.0MSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Changed: -22.6%
$53.0M to $41.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +13.7%
$409.0M to $465.0MNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: −1.4 pts
56.6% to 55.2%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +2.4 pts
-1.8% to 0.6%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +2.6 pts
-2.6% to 0.0%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 6.5% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
This company has not reported enough of the required figures to calculate this score.
| 0.28x |
| ALGNALIGN TECHNOLOGY INC | 8.7/10 | 6/8 | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
| Median of peers | 8.7/10 | — | 0.9% | 10.2% | 27.04x | 0.54x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Was granted or awarded shares — 836 shares
Holds 40,409 shares after this filing.
Reported another kind of transaction — 252,813,348 shares
Holds 0 shares after this filing.
Was granted or awarded shares — 11,877 shares
Holds 11,877 shares after this filing.
Was granted or awarded shares — 3,374 shares
Holds 15,169 shares after this filing.
Was granted or awarded shares — 11,877 shares
Holds 11,877 shares after this filing.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q1 FY2027
Revenue +16.6% · Operating margin +2.4 pts · Operating income turned positive — against Q1 FY2027
Published results · Made a Regulation FD disclosure
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2026
Revenue +14.3% · Profit margin −2.9 pts · Profit $120.0M wider — against FY2025
Read the filingHad a director or senior officer leave or join · Received shareholder director nominations · Reported another event
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2026
Revenue +15.0% · Operating margin −15.7 pts · Operating income turned negative — against Q3 FY2026
Read the filingHad a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingSigned a material agreement · Completed an acquisition or disposal · Took on a direct financial obligation · Sold shares outside a public offering · Changed the rights attached to its shares · Had a director or senior officer leave or join · Amended its charter or changed its financial year · Made a Regulation FD disclosure
Read the filingRegistration statement for an offering of securities
Read the filingRegistration statement for an offering of securities
Read the filingRegistration statement for an offering of securities
Read the filingRegistration statement for an offering of securities
Read the filingSource: Exhibit 21 of the 10-K filed 2026-06-29. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
Yahoo ·
Is Medtronic Stock A Buy Now That Sales Growth Has Picked Up?
Yahoo ·
These stocks have an unusual volume in today's session
ChartMill ·
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic
Benzinga ·
MiniMed Completes Separation from Medtronic
Yahoo ·
Medtronic Completes Separation of MiniMed Group, Inc.
Yahoo ·
Jim Cramer: This Health Care Stock Is A ‘Winner’, X-Energy Is ‘Losing Too Much Money’
Benzinga ·
BC-Most Active Stocks
Yahoo ·
Medtronic Announces Final Results of MiniMed Group, Inc. Exchange Offer
Yahoo ·
Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
Yahoo ·
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Benzinga ·
Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer
Yahoo ·
Primary sources and further research